

2007/2008 Lung Health Funding/Clinical Trials

RESEARCHER	AWARD AMOUNT	AGENCY	AWARD TYPE	TITLE
Levy, Robert	\$1,110.00	Actelion Pharmaceuticals Canada Inc.	Clinical Trial	A double-blind, randomized, placebo-controlled, multicenter study to assess the efficacy, safety and tolerability of bosentan in patients with idiopathic pulmonary fibrosis
Wilcox, Pearce G.	\$23,010.00	Actelion Pharmaceuticals Canada Inc.	Clinical Trial	Protocol AC-052-321 BUILD 3: Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Event-Driven, Group Sequential, Phase
Sin, Donald	\$4,000.00	AstraZeneca AB	Clinical Trial	Protocol D5892C00015 (CLIMB): a 12-week, double-blind, randomised, parallel group, multi-centre study to evaluate efficacy and safety of budesonide/ formoterol (symbicort(r) turbuhaler(r)) 320/9 ug one inhalation twice daily on top of tiot
Bai, Tony	\$9,375.00	Boehringer Ingelheim (Canada) Ltd.	Clinical Trial	Protocol 1222.6 (Project Nickname BI 1744 CL): Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy (Bronchodilation) and Safety of 4 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (2up, 5up
Wilcox, Pearce G.	\$24,340.88	Boehringer Ingelheim (Canada) Ltd.	Clinical Trial	205.372-Spiriva Respimat(TM) Study: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Long Term (one-year) Efficacy and Safety of Tiotropium Inhalation Solution 5ug (2 puffs of 2.5ug) Delivered by the Respimat
Fitzgerald, Mark	\$15,300.00	Canadian Institutes of Health Research (CIHR)	Clinical Trial	IICT: Asthma in Obese Subjects - Diagnostic & Therapeutic Strategies
Knight, Darryl	\$25,000.00	Centocor Inc.	Clinical Trial	SA: Development and Cellular Mechanisms involved in the Pathological Changes to the epithelium in asthma.
Russell, James	\$30,201.20	Chiron Corp.	Clinical Trial	A phase 3, multicentre, randomized, placebo-controlled, double-blind, three-arm study to evaluate the safety and efficacy of Tifacogin (recombinant tissue factor pathway inhibitor) administration in subjects with sever community-acquired pneumon
Wilcox, Pearce G.	\$7,750.00	Corus Pharma Inc.	Clinical Trial	A Phase 3, Double-Blind, Multicenter, Multinational, Randomized, Placebo-Controlled Trial Evaluating Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients with P. Aeruginosa (AIR-CF1)
Innis, Sheila	\$26,114.25	Cystic Fibrosis Foundation Therapeutics Inc.	Clinical Trial	Choline Nutrition in Children with Cystic Fibrosis
Fleetham, John	\$1,000.00	Donations for Health Science Research	Clinical Trial	UBC Vancouver Hospital Respiratory Faculty Development Fund

2007/2008 Lung Health Funding/Clinical Trials

RESEARCHER	AWARD AMOUNT	AGENCY	AWARD TYPE	TITLE
Levy, Robert	\$5,109.45	Encysive L.P.	Clinical Trial	Protocol FPH03 STRIDE III: Long-Term Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients with Pulmonary Arterial Hypertension
Fitzgerald, Mark	\$13,552.00	GlaxoSmithKline (Canada) Inc.	Clinical Trial	SCO100250: A Randomized, Double-Blind, Parallel Group, 52-week Study to Compare the Effect of the Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50mcg BID with Salmeterol DISKUS 50mcg BID on the Annual Rate of Moderate/..
Sin, Donald	\$5,353.00	GlaxoSmithKline (Canada) Inc.	Clinical Trial	Protocol AIM (ADC105931): A Randomized, Double-Blind, Parallel-Group, 14-Week Study to Evaluate the Anti-Inflammatory Effect of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg BID Compared to Salmeterol DISKUS 50mcg BID in Subjects With
Wilcox, Pearce G.	\$49,338.66	InterMune Inc.	Clinical Trial	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Bai, Tony	\$890.00	Intermune Pharmaceuticals Inc.	Clinical Trial	A randomized, double-blind, placebo-controlled phase II study of the safety and efficacy of subcutaneous recombinant interferon-γ1b (rIFN-γ 1b) in patients with idiopathic pulmonary fibrosis
Wilcox, Pearce G.	\$9,778.50	Intermune Pharmaceuticals Inc.	Clinical Trial	A randomized, double-blind, placebo-controlled, phase 3 study of the safety and efficacy of Interferon Gamma-1b in patients with idiopathic pulmonary fibrosis. (The INSPIRE Trial: International study of Survival outcomes in IPF with InterFERon)
Ostrow, David	\$25,695.93	Lilly ICOS	Clinical Trial	Protocols LVGX and LVGY: A Randomized Double-Blind, Study to Evaluate the Long-Term Safety and Efficacy of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension
Fitzgerald, Mark	\$22,400.00	National Cancer Institute of Canada - Clinical Trials Group	Clinical Trial	IICT: A Phase III Randomized Study of Exemestane vs. Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Van Eeden, Stephanus	\$20,000.00	National Institutes of Health	Clinical Trial	IICT: Diesel Exhaust and Atherosclerotic Plaque Stability
Wilcox, Pearce G.	\$17,381.25	Perceptronix Medical Inc.	Clinical Trial	Spectral Imaging of Early Lung Cancers and Pre-Cancerous Lesions
Wilcox, Pearce G.	\$578.75	Pharmaxis Ltd.	Clinical Trial	DPM-CF-202: A Phase 2A, Randomised, Open Label, Dose Response Study to Determine the Optimum Dose of Dry Powder Mannitol Required to Generate Clinical Improvement in Patients with Cystic Fibrosis
Ayas, Najib	\$100,000.00	Respironics Inc.	Clinical Trial	Role of Telemedicine in the Initiation of Nasal CPAP
Knight, Darryl	\$49,435.15	Sepracor Inc.	Clinical Trial	The role of (R) and (S) enantiomers of albuterol in mucosal injury and repair in pediatric asthma

2007/2008 Lung Health Funding/Clinical Trials

RESEARCHER	AWARD AMOUNT	AGENCY	AWARD TYPE	TITLE
Road, Jeremy	\$55,009.93	Spiration Inc.	Clinical Trial	CPR-0003: Study to Find Out If a New Medical Device Called the Intra-Bronchial Valve (IBV) is Safe and Effective to Use in Subjects With Severe Emphysema
Sin, Donald	\$67,680.65	St. Joseph's Health System	Clinical Trial	IICT: Can Advair and Flovent reduce systemic inflammation related to COPD? A multi-center randomized controlled Trial.
Bai, Tony	\$7,212.40	Topigen Pharmaceuticals Inc.	Clinical Trial	protocol topigen asthma study: a phase ii, randomized, double-blind, placebo-controlled, parallel-groups, multicenter study to evaluate and compare the safety, tolerability and efficacy of two doses OF INHALED TPI ASM8 (0.25 MG AND 0.5